EE05294B1 - TALL-1-ga seostuv ainekompositsioon - Google Patents

TALL-1-ga seostuv ainekompositsioon

Info

Publication number: EE05294B1
Authority: EE; Estonia
Prior art keywords: tall; seq; domain; matter; vehicle
Prior art date: 2001-05-11

Application number

EEP200300552A

Other languages

English (en)

Estonian (et)

Inventor

Min Hosung

Hsu Hailing

Xiong Fei

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-11

Filing date

2002-05-13

Publication date

2010-04-15

2002-05-13 Application filed by Amgen Inc. filed Critical Amgen Inc.

2004-02-16 Publication of EE200300552A publication Critical patent/EE200300552A/xx

2010-04-15 Publication of EE05294B1 publication Critical patent/EE05294B1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Crystallography & Structural Chemistry (AREA)
Virology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Transplantation (AREA)
Dermatology (AREA)

EEP200300552A 2001-05-11 2002-05-13 TALL-1-ga seostuv ainekompositsioon EE05294B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29019601P	2001-05-11	2001-05-11
PCT/US2002/015273 WO2002092620A2 (en)	2001-05-11	2002-05-13	Peptides and related molecules that bind to tall-1

Publications (2)

Publication Number	Publication Date
EE200300552A EE200300552A (et)	2004-02-16
EE05294B1 true EE05294B1 (et)	2010-04-15

Family

ID=23114926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300552A EE05294B1 (et)	2001-05-11	2002-05-13	TALL-1-ga seostuv ainekompositsioon

Country Status (30)

Country	Link
US (5)	US7259137B2 (xx)
EP (4)	EP1385882B9 (xx)
JP (1)	JP4516719B2 (xx)
KR (1)	KR100902687B1 (xx)
CN (3)	CN1970077A (xx)
AT (2)	ATE549354T1 (xx)
AU (1)	AU2002342669C1 (xx)
BG (1)	BG66270B1 (xx)
BR (1)	BR0209546A (xx)
CA (1)	CA2446189C (xx)
CY (1)	CY1107131T1 (xx)
CZ (1)	CZ304592B6 (xx)
DE (1)	DE60222882T2 (xx)
DK (1)	DK1385882T3 (xx)
EA (1)	EA010435B1 (xx)
EE (1)	EE05294B1 (xx)
ES (3)	ES2387546T3 (xx)
HK (3)	HK1059269A1 (xx)
HU (1)	HU229910B1 (xx)
IL (2)	IL158719A0 (xx)
MX (1)	MXPA03010210A (xx)
NO (1)	NO331785B1 (xx)
NZ (2)	NZ542878A (xx)
PL (2)	PL210546B1 (xx)
PT (1)	PT1385882E (xx)
RS (1)	RS51708B (xx)
SI (1)	SI1385882T1 (xx)
SK (1)	SK288175B6 (xx)
WO (1)	WO2002092620A2 (xx)
ZA (1)	ZA200308513B (xx)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212004B2 (en) *	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7879328B2 (en) *	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609016T3 (es) *	2000-06-16	2017-04-18	Human Genome Sciences, Inc.	Anticuerpos que se unen inmunoespecíficamente a BLyS
US20030091565A1 (en) *	2000-08-18	2003-05-15	Beltzer James P.	Binding polypeptides and methods based thereon
EP2267019A3 (en)	2000-08-18	2011-07-06	Human Genome Sciences, Inc.	Binding polypeptides for B lymphocyte stimulator protein (BLyS)
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ES2387546T3 (es) *	2001-05-11	2012-09-25	Amgen Inc.	Péptidos y moléculas relacionadas que se unen a TALL-1
US7112410B1 (en)	2001-08-29	2006-09-26	Human Genome Sciences, Inc.	Human tumor necrosis factor TR21 and methods based thereon
PL378879A1 (pl)	2002-12-30	2006-05-29	Amgen Inc.	Terapia skojarzona z czynnikami kostymulującymi
AU2004233164B2 (en)	2003-03-28	2009-10-08	Biogen Ma Inc.	Truncated BAFF receptors
KR20060027801A (ko)	2003-06-05	2006-03-28	제넨테크, 인크.	Ｂ 세포 장애에 대한 조합 요법
US7605120B2 (en) *	2003-10-22	2009-10-20	Amgen Inc.	Antagonists of the brandykinin B1 receptor
EP1709072A1 (en)	2004-01-29	2006-10-11	Genentech, Inc.	Variants of the extracellular domain of bcma and uses thereof
ES2427046T3 (es) *	2004-06-21	2013-10-28	Galapagos N.V.	Métodos y medios para el tratamiento de la osteoartritis
CN101103045B (zh)	2004-09-24	2015-11-25	安姆根有限公司	修饰的Fc分子
CN100378122C (zh) *	2004-12-03	2008-04-02	中国人民解放军第三军医大学	B淋巴细胞刺激因子抑制肽及其制备方法
KR20080031684A (ko)	2005-06-14	2008-04-10	암젠 인코포레이티드	자가 - 완충성 단백질 제형
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
US9168286B2 (en) *	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en)	2005-10-13	2013-05-02	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive diseases
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
AU2006318539B2 (en)	2005-11-23	2012-09-13	Genentech, Inc.	Methods and compositions related to B cell assays
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
US9283260B2 (en) *	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
US7981425B2 (en)	2006-06-19	2011-07-19	Amgen Inc.	Thrombopoietic compounds
US20090252703A1 (en) *	2006-10-19	2009-10-08	Gegg Jr Colin V	Use of alcohol co-solvents to improve pegylation reaction yields
AU2008262490B2 (en)	2007-05-22	2011-11-17	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
EP2197421A1 (en) *	2007-08-31	2010-06-23	Amgen, Inc	Solid-state protein formulation
AU2008304111B2 (en)	2007-09-27	2014-04-24	Amgen Inc.	Pharmaceutical formulations
EP3381445B1 (en)	2007-11-15	2023-10-25	Amgen Inc.	Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
EP2396035A4 (en) *	2009-02-12	2012-09-12	Human Genome Sciences Inc	USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
MX347291B (es)	2009-03-20	2017-04-17	Amgen Inc	Inmunoglobulinas portadoras y usos de las mismas.
CN102369215B (zh)	2009-04-02	2015-01-21	罗切格利卡特公司	包含全长抗体和单链Fab片段的多特异性抗体
CN102597268B (zh)	2009-09-03	2017-09-22	弗·哈夫曼-拉罗切有限公司	用于治疗、诊断和监控类风湿性关节炎的方法
NZ598962A (en)	2009-09-16	2014-12-24	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
EP2490957B1 (en)	2009-10-23	2016-11-23	Amgen, Inc	Vial adapter and system
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
WO2011133886A2 (en)	2010-04-23	2011-10-27	Genentech, Inc.	Production of heteromultimeric proteins
PL2575935T5 (pl)	2010-06-07	2023-12-11	Amgen Inc.	Urządzenie do podawania leku
WO2012021773A1 (en)	2010-08-13	2012-02-16	Genentech, Inc.	Antibodies to il-1beta and il-18, for treatment of disease
JP5758004B2 (ja)	2010-08-24	2015-08-05	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
WO2012040518A2 (en)	2010-09-22	2012-03-29	Amgen Inc.	Carrier immunoglobulins and uses thereof
WO2012085111A1 (en)	2010-12-23	2012-06-28	F. Hoffmann-La Roche Ag	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
BR112013019499B1 (pt)	2011-02-04	2023-01-10	Genentech, Inc.	Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
WO2012118750A2 (en)	2011-02-28	2012-09-07	Genentech, Inc.	Biological markers and methods for predicting response to b-cell antagonists
EP2691065B1 (en)	2011-03-31	2017-03-01	Amgen Inc.	Vial adapter and system
CA3145238A1 (en)	2011-04-20	2012-10-26	Amgen Inc.	Autoinjector apparatus
DE202012012998U1 (de)	2011-08-31	2014-06-13	Daniel Elias	Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
CN104093744A (zh)	2011-10-11	2014-10-08	弗·哈夫曼-拉罗切有限公司	双特异性抗体的改进的组装
SI3335747T1 (sl)	2011-10-14	2021-08-31	Amgen Inc.	Injektor in postopek sestave
BR112014018471A2 (pt)	2012-01-31	2017-07-04	Genentech Inc	anticorpos anti-ige m1' e métodos para o seu uso
MX2014009565A (es)	2012-02-10	2014-11-10	Genentech Inc	Anticuerpos monocatenarios y otros heteromultimeros.
CA2862516C (en)	2012-03-27	2023-02-14	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
JP6309002B2 (ja)	2012-06-27	2018-04-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
CN104395339A (zh)	2012-06-27	2015-03-04	弗·哈夫曼-拉罗切有限公司	用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
SI3081249T1 (sl)	2012-11-21	2021-03-31	Amgen Inc.	Naprava za dajanje zdravila
WO2014120619A2 (en)	2013-01-30	2014-08-07	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use in treating metabolic disorders
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
JOP20140087B1 (ar)	2013-03-13	2021-08-17	Amgen Inc	بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
CA2904725C (en)	2013-03-15	2022-04-12	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
EP3593839A1 (en)	2013-03-15	2020-01-15	Amgen Inc.	Drug cassette
CN113559363B (zh)	2013-03-22	2023-10-31	美国安进公司	注射器及装配方法
WO2015056356A1 (en)	2013-10-17	2015-04-23	The Nippon Synthetic Chemical Industry Co., Ltd.	Crosslinkable polymer
MX2016005315A (es)	2013-10-24	2016-08-11	Amgen Inc	Sistema de administracion de farmacos con control sensible a la temperatura.
KR102458637B1 (ko)	2013-10-24	2022-10-24	암겐 인코포레이티드	주입기 및 조립 방법
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
MX2016014409A (es)	2014-05-06	2017-01-20	Genentech Inc	Produccion de proteinas heteromultimericas usando celulas de mamifero.
MX2016014561A (es)	2014-05-07	2017-06-21	Amgen Inc	Autoinyetor con elementos reductores del shock.
EP4036924A1 (en)	2014-06-03	2022-08-03	Amgen, Inc	Devices and methods for assisting a user of a drug delivery device
CN106573966B (zh)	2014-07-30	2022-03-01	Ngm生物制药有限公司	用于治疗代谢异常的组合物和方法
EP3943135A3 (en)	2014-10-14	2022-06-29	Amgen Inc.	Drug injection device with visual and audible indicators
CA2961587A1 (en)	2014-10-31	2016-05-06	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
PL3227332T3 (pl)	2014-12-03	2020-06-15	F. Hoffmann-La Roche Ag	Wielospecyficzne przeciwciała
EP3233163B1 (en)	2014-12-19	2021-10-13	Amgen Inc.	Drug delivery device with proximity sensor
JP2017538512A (ja)	2014-12-19	2017-12-28	アムジエン・インコーポレーテツド	ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
AU2016220141B2 (en)	2015-02-17	2018-07-12	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en)	2015-02-27	2021-12-15	Amgen Inc.	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
HRP20231544T1 (hr)	2015-08-13	2024-03-15	Amgen Inc.	Nabijena dubinska filtracija proteina koji vežu antigene
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
EP3386573B1 (en)	2015-12-09	2019-10-02	Amgen Inc.	Auto-injector with signaling cap
WO2017120178A1 (en)	2016-01-06	2017-07-13	Amgen Inc.	Auto-injector with signaling electronics
US11200298B2 (en)	2016-03-15	2021-12-14	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
IL261666B1 (en)	2016-03-31	2024-05-01	Ngm Biopharmaceuticals Inc	Related proteins and methods of using them
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en)	2016-05-13	2017-11-16	Amgen Inc.	Vial sleeve assembly
EP3458988B1 (en)	2016-05-16	2023-10-18	Amgen Inc.	Data encryption in medical devices with limited computational capability
US11541176B2 (en)	2016-06-03	2023-01-03	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en)	2016-07-01	2019-05-08	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
EP3532127A1 (en)	2016-10-25	2019-09-04	Amgen Inc.	On-body injector
WO2018136398A1 (en)	2017-01-17	2018-07-26	Amgen Inc.	Injection devices and related methods of use and assembly
EP3582829A1 (en)	2017-02-17	2019-12-25	Amgen Inc.	Insertion mechanism for drug delivery device
MX2019009625A (es)	2017-02-17	2019-10-09	Amgen Inc	Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
WO2018165143A1 (en)	2017-03-06	2018-09-13	Amgen Inc.	Drug delivery device with activation prevention feature
MX2019010543A (es)	2017-03-07	2019-10-21	Amgen Inc	Insercion de agujas por sobrepresion.
IL268386B2 (en)	2017-03-09	2023-11-01	Amgen Inc	Insertion mechanism for a drug delivery device
BR112019020053B1 (pt)	2017-03-28	2023-10-10	Amgen Inc	Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina
EP3632933A4 (en)	2017-06-01	2021-03-03	Seoul National University R & DB Foundation	NOVEL ANTI-CD40 ANTIBODIES AND USES THEREOF
AU2018280054B2 (en)	2017-06-08	2023-07-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
AU2018282077B2 (en)	2017-06-08	2023-11-23	Amgen Inc.	Torque driven drug delivery device
EP3641857A1 (en)	2017-06-22	2020-04-29	Amgen Inc.	Device activation impact/shock reduction
WO2018237225A1 (en)	2017-06-23	2018-12-27	Amgen Inc.	ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
EP3651832B1 (en)	2017-07-14	2023-12-13	Amgen Inc.	Needle insertion-retraction system having dual torsion spring system
WO2019018169A1 (en)	2017-07-21	2019-01-24	Amgen Inc.	PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
MA49677A (fr)	2017-07-25	2021-04-21	Amgen Inc	Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
JP7242562B2 (ja)	2017-07-25	2023-03-20	アムジエン・インコーポレーテツド	容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
US20200164155A1 (en)	2017-08-09	2020-05-28	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en)	2017-08-18	2019-02-21	Amgen Inc.	BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
ES2939292T3 (es)	2017-10-04	2023-04-20	Amgen Inc	Adaptador de flujo para dispositivo de administración de fármacos
WO2019070552A1 (en)	2017-10-06	2019-04-11	Amgen Inc.	DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
US11464903B2 (en)	2017-10-09	2022-10-11	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
EP3703779A1 (en)	2017-11-03	2020-09-09	Amgen Inc.	Systems and approaches for sterilizing a drug delivery device
EP3706830A1 (en)	2017-11-06	2020-09-16	Amgen Inc.	Drug delivery device with placement and flow sensing
WO2019090303A1 (en)	2017-11-06	2019-05-09	Amgen Inc.	Fill-finish assemblies and related methods
SG11202002966QA (en)	2017-11-10	2020-05-28	Amgen Inc	Plungers for drug delivery devices
MX2020005066A (es)	2017-11-16	2020-08-20	Amgen Inc	Autoinyector con deteccion de detencion y punto final.
AU2018368340B2 (en)	2017-11-16	2024-03-07	Amgen Inc.	Door latch mechanism for drug delivery device
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
US20210260279A1 (en)	2018-07-24	2021-08-26	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
MX2021000749A (es)	2018-07-24	2021-03-29	Amgen Inc	Dispositivos de suministro para administrar farmacos.
WO2020023444A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
US20210228797A1 (en)	2018-07-31	2021-07-29	Amgen Inc.	Fluid path assembly for a drug delivery device
WO2020068623A1 (en)	2018-09-24	2020-04-02	Amgen Inc.	Interventional dosing systems and methods
EP3856283A1 (en)	2018-09-28	2021-08-04	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
CA3110529A1 (en)	2018-10-02	2020-04-09	Amgen Inc.	Injection systems for drug delivery with internal force transmission
EP3860686A1 (en)	2018-10-05	2021-08-11	Amgen Inc.	Drug delivery device having dose indicator
JP2022504769A (ja)	2018-10-15	2022-01-13	アムジエン・インコーポレーテツド	ダンピング機構を有する薬物送達装置
WO2020081480A1 (en)	2018-10-15	2020-04-23	Amgen Inc.	Platform assembly process for drug delivery device
US20220031939A1 (en)	2018-11-01	2022-02-03	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
MA54048A (fr)	2018-11-01	2022-02-09	Amgen Inc	Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
MX2021012557A (es)	2019-04-24	2021-11-12	Amgen Inc	Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
AU2020337250A1 (en)	2019-08-23	2022-03-03	Amgen Inc.	Drug delivery device with configurable needle shield engagement components and related methods
BR112023024278A2 (pt)	2021-05-21	2024-01-30	Amgen Inc	Método de otimizar uma receita de enchimento para um recipiente de fármacos

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US3941763A (en)	1975-03-28	1976-03-02	American Home Products Corporation	PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en)	1979-04-06	1981-09-15	Allied Corporation	Macromolecular highly branched homogeneous compound based on lysine units
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US4496689A (en) *	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0318512B1 (en)	1986-08-18	1998-06-17	Emisphere Technologies, Inc.	Delivery systems for pharmacological agents
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
EP0315456B1 (en)	1987-11-05	1994-06-01	Hybritech Incorporated	Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US6018026A (en) *	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en) *	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
AU643141B2 (en)	1991-03-15	1993-11-04	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
ATE156158T1 (de)	1992-04-14	1997-08-15	Cornell Res Foundation Inc	Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US5417972A (en) *	1993-08-02	1995-05-23	The Board Of Trustees Of The Leland Stanford Junior University	Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5470952A (en)	1993-10-20	1995-11-28	Regeneron Pharmaceuticals, Inc.	CNTF and IL-6 antagonists
US5922545A (en) *	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE4435919C1 (de)	1994-10-07	1995-12-07	Deutsches Krebsforsch	Zinkfinger-DNA, -Protein und ihre Verwendung
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
DE69731289D1 (de)	1996-03-18	2004-11-25	Univ Texas	Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
ES2190543T3 (es)	1996-10-08	2003-08-01	Bisys B V U	Procedimientos y sistemas que permiten seleccionar peptidos y proteinas que tienen una afinidad especifica respecto a un blanco.
DK0939804T4 (da)	1996-10-25	2011-07-18	Human Genome Sciences Inc	Neutrokin-alpha
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
WO1998027114A2 (en)	1996-12-17	1998-06-25	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
WO1998055620A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
CA2292835A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EA200000311A1 (ru)	1997-09-12	2000-10-30	Апотек Р Энд Д Са	Новый белок иммунной системы - кау
AU2212299A (en)	1998-01-05	1999-07-26	Genentech Inc.	Compositions and methods for the treatment of tumor
WO1999062951A1 (en) *	1998-06-04	1999-12-09	Shanghai Second Medical University	A human zinc finger protein gene (bmzf3)
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
NZ512753A (en)	1999-01-07	2003-10-31	Zymogenetics Inc	Soluble receptor BR43x2 related proteins useful for inhibiting ztnf4
HUP0105283A3 (en)	1999-01-25	2004-08-30	Biogen Idec Ma Inc Cambridge	Baff, inhibitors thereof and their use in the modulation of b-cell response
US20030095967A1 (en)	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000047740A2 (en)	1999-02-12	2000-08-17	Amgen Inc.	Tnf-related proteins
US20030022233A1 (en)	1999-04-30	2003-01-30	Raymond G. Goodwin	Methods of use of the taci/taci-l interaction
WO2000068378A1 (en)	1999-05-06	2000-11-16	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
AU6064400A (en)	1999-07-02	2001-01-22	Genentech Inc.	Fusion peptides comprising a peptide ligand domain and a multimerization domain
AU3695801A (en)	2000-02-11	2001-11-20	Amgen, Inc.	Receptor from tnf family
EP2267019A3 (en)	2000-08-18	2011-07-06	Human Genome Sciences, Inc.	Binding polypeptides for B lymphocyte stimulator protein (BLyS)
US20030091565A1 (en)	2000-08-18	2003-05-15	Beltzer James P.	Binding polypeptides and methods based thereon
ES2387546T3 (es) *	2001-05-11	2012-09-25	Amgen Inc.	Péptidos y moléculas relacionadas que se unen a TALL-1
AR035119A1 (es)	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
PL378879A1 (pl) *	2002-12-30	2006-05-29	Amgen Inc.	Terapia skojarzona z czynnikami kostymulującymi
WO2006010057A2 (en) *	2004-07-08	2006-01-26	Amgen Inc.	Therapeutic peptides
US8008453B2 (en) *	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
KR101104556B1 (ko)	2006-12-05	2012-01-11	가부시키가이샤 고베 세이코쇼	인쇄판용 고강도 알루미늄 합금판
JOP20140087B1 (ar) *	2013-03-13	2021-08-17	Amgen Inc	بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) *	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
WO2020175345A1 (ja)	2019-02-27	2020-09-03	株式会社村田製作所	コネクタ、コネクタセット

2002
- 2002-05-13 ES ES10178373T patent/ES2387546T3/es not_active Expired - Lifetime
- 2002-05-13 SK SK1489-2003A patent/SK288175B6/sk not_active IP Right Cessation
- 2002-05-13 CZ CZ2003-3291A patent/CZ304592B6/cs not_active IP Right Cessation
- 2002-05-13 JP JP2002589503A patent/JP4516719B2/ja not_active Expired - Lifetime
- 2002-05-13 US US10/145,206 patent/US7259137B2/en not_active Expired - Lifetime
- 2002-05-13 BR BR0209546-7A patent/BR0209546A/pt not_active Application Discontinuation
- 2002-05-13 SI SI200230645T patent/SI1385882T1/sl unknown
- 2002-05-13 EP EP02769739A patent/EP1385882B9/en not_active Expired - Lifetime
- 2002-05-13 WO PCT/US2002/015273 patent/WO2002092620A2/en active IP Right Grant
- 2002-05-13 NZ NZ542878A patent/NZ542878A/en not_active IP Right Cessation
- 2002-05-13 RS YU95203A patent/RS51708B/sr unknown
- 2002-05-13 HU HU0700125A patent/HU229910B1/hu not_active IP Right Cessation
- 2002-05-13 CN CNA2006101537090A patent/CN1970077A/zh active Pending
- 2002-05-13 CN CNB028140095A patent/CN100448891C/zh not_active Expired - Fee Related
- 2002-05-13 MX MXPA03010210A patent/MXPA03010210A/es active IP Right Grant
- 2002-05-13 EP EP20100178373 patent/EP2292655B1/en not_active Expired - Lifetime
- 2002-05-13 IL IL15871902A patent/IL158719A0/xx unknown
- 2002-05-13 EA EA200301241A patent/EA010435B1/ru not_active IP Right Cessation
- 2002-05-13 EE EEP200300552A patent/EE05294B1/xx not_active IP Right Cessation
- 2002-05-13 DE DE60222882T patent/DE60222882T2/de not_active Expired - Lifetime
- 2002-05-13 AT AT10178373T patent/ATE549354T1/de active
- 2002-05-13 KR KR1020037014672A patent/KR100902687B1/ko active IP Right Grant
- 2002-05-13 PL PL369570A patent/PL210546B1/pl unknown
- 2002-05-13 CN CNA2006101537137A patent/CN1970078A/zh active Pending
- 2002-05-13 DK DK02769739T patent/DK1385882T3/da active
- 2002-05-13 CA CA2446189A patent/CA2446189C/en not_active Expired - Fee Related
- 2002-05-13 EP EP20070019762 patent/EP1921088B1/en not_active Expired - Lifetime
- 2002-05-13 AU AU2002342669A patent/AU2002342669C1/en not_active Ceased
- 2002-05-13 EP EP14180109.2A patent/EP2845864A3/en not_active Withdrawn
- 2002-05-13 PT PT02769739T patent/PT1385882E/pt unknown
- 2002-05-13 PL PL39331702A patent/PL393317A1/pl unknown
- 2002-05-13 ES ES02769739T patent/ES2295404T3/es not_active Expired - Lifetime
- 2002-05-13 AT AT02769739T patent/ATE375361T1/de active
- 2002-05-13 NZ NZ529267A patent/NZ529267A/en not_active IP Right Cessation
- 2002-05-13 ES ES07019762.9T patent/ES2527471T3/es not_active Expired - Lifetime
2003
- 2003-10-31 ZA ZA200308513A patent/ZA200308513B/en unknown
- 2003-11-02 IL IL158719A patent/IL158719A/en not_active IP Right Cessation
- 2003-11-10 NO NO20034980A patent/NO331785B1/no not_active IP Right Cessation
- 2003-11-12 BG BG108349A patent/BG66270B1/bg unknown
2004
- 2004-02-25 HK HK04101344A patent/HK1059269A1/xx not_active IP Right Cessation
2005
- 2005-11-10 US US11/272,521 patent/US7737111B2/en not_active Expired - Fee Related
2008
- 2008-01-09 CY CY081100030T patent/CY1107131T1/el unknown
2010
- 2010-05-26 US US12/788,137 patent/US8507426B2/en not_active Expired - Fee Related
2011
- 2011-06-04 HK HK11105624A patent/HK1151545A1/xx not_active IP Right Cessation
2013
- 2013-07-09 US US13/938,141 patent/US9139645B2/en not_active Expired - Fee Related
2015
- 2015-08-21 HK HK15108146.9A patent/HK1207390A1/xx unknown
- 2015-09-21 US US14/860,381 patent/US20160176926A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7737111B2 (en)	2010-06-15
WO2002092620A3 (en)	2003-08-21
DE60222882D1 (de)	2007-11-22
HK1059269A1 (en)	2004-06-25
HU229910B1 (hu)	2014-12-29
PL210546B1 (pl)	2012-01-31
US20160176926A1 (en)	2016-06-23
PT1385882E (pt)	2008-01-11
PL369570A1 (en)	2005-05-02
JP2004533249A (ja)	2004-11-04
EP1921088A3 (en)	2009-01-14
AU2002342669C1 (en)	2010-10-07
HUP0700125A3 (en)	2010-01-28
EA010435B1 (ru)	2008-08-29
NO20034980D0 (no)	2003-11-10
ES2387546T3 (es)	2012-09-25
SI1385882T1 (sl)	2008-04-30
US9139645B2 (en)	2015-09-22
RS51708B (sr)	2011-10-31
CN1970078A (zh)	2007-05-30
EP1385882B9 (en)	2009-08-12
SK288175B6 (sk)	2014-04-02
EE200300552A (et)	2004-02-16
EA200301241A1 (ru)	2004-08-26
HUP0700125A2 (en)	2007-06-28
CA2446189A1 (en)	2002-11-21
KR100902687B1 (ko)	2009-06-15
EP2845864A3 (en)	2015-06-10
PL393317A1 (pl)	2011-05-23
EP2292655A1 (en)	2011-03-09
CN1535281A (zh)	2004-10-06
US7259137B2 (en)	2007-08-21
BR0209546A (pt)	2004-06-29
CN1970077A (zh)	2007-05-30
HK1207390A1 (en)	2016-01-29
CY1107131T1 (el)	2012-10-24
DK1385882T3 (da)	2008-02-11
NZ529267A (en)	2006-05-26
EP1385882A4 (en)	2005-09-21
KR20040012815A (ko)	2004-02-11
YU95203A (sh)	2006-05-25
DE60222882T2 (de)	2008-07-10
CZ20033291A3 (cs)	2004-11-10
IL158719A (en)	2013-09-30
NZ542878A (en)	2007-06-29
US20030195156A1 (en)	2003-10-16
ATE375361T1 (de)	2007-10-15
EP1921088A2 (en)	2008-05-14
ES2295404T3 (es)	2008-04-16
NO20034980L (no)	2003-12-12
HK1151545A1 (en)	2012-02-03
ZA200308513B (en)	2004-09-16
BG108349A (bg)	2004-11-30
SK14892003A3 (en)	2004-11-03
JP4516719B2 (ja)	2010-08-04
EP1921088B1 (en)	2014-10-08
EP1385882B1 (en)	2007-10-10
EP2292655B1 (en)	2012-03-14
ATE549354T1 (de)	2012-03-15
CN100448891C (zh)	2009-01-07
CA2446189C (en)	2011-10-18
MXPA03010210A (es)	2004-03-10
US20100240590A1 (en)	2010-09-23
ES2527471T3 (es)	2015-01-26
EP2845864A2 (en)	2015-03-11
NO331785B1 (no)	2012-03-26
US8507426B2 (en)	2013-08-13
BG66270B1 (bg)	2012-11-30
US20140234334A1 (en)	2014-08-21
AU2002342669B2 (en)	2005-09-22
CZ304592B6 (cs)	2014-07-23
IL158719A0 (en)	2004-05-12
EP1385882A2 (en)	2004-02-04
WO2002092620A2 (en)	2002-11-21
US20060135431A1 (en)	2006-06-22

Legal Events

Date	Code	Title	Description
2010-02-15	HK1A	Erratum in gazette
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2020-12-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20200513

Publication	Publication Date	Title
EE05294B1 (et)	2010-04-15	TALL-1-ga seostuv ainekompositsioon
TR199901473T2 (xx)	1999-10-21	Ha�ere �ld�r�c� 1-arilpirazoller
FI935529A (fi)	1994-06-11	Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
DE60321847D1 (de)	2008-08-14	Hydrogel-Klebstoffe zur Verwendung auf Fasern besetzten Oberflächen
PL330952A1 (en)	1999-08-02	Composition having antimicrobial properties and method of disinfecting surfaces
DE69729583D1 (de)	2004-07-22	N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
GB9908934D0 (en)	1999-06-16	Liquid crystalline compounds
CA2210848A1 (fr)	1998-01-25	Utilisation de derives de la melatonine pour la depigmentation de la peau et compositions les comprenant
DE59703471D1 (de)	2001-06-07	Betain-geminitenside auf der basis von aminen
ATE240953T1 (de)	2003-06-15	Carbazolcarboxamide als 5-ht1f agonisten
BRPI0416106A (pt)	2007-01-02	ácidos 4 -((fenoxialquil)tio)-fenoxiacéticos e análogos
ES2142490T3 (es)	2000-04-16	Ciclopeptolidos.
WO2003029895A8 (de)	2003-11-20	Effiziente nichtlinear-optische polymere mit hoher polungsstabilität
ES2111897T3 (es)	1998-03-16	Agentes de revestimiento con formacion de pelicula termoendurecible y su empleo.
BR9814188A (pt)	2000-10-03	"agonistas de 5-ht1f"
ATE275964T1 (de)	2004-10-15	Verwendung von betalycan zur verminderung der narbenbildung
EP1067138A4 (en)	2004-11-03	HYDROXYPROLINE DERIVATIVES
TR199902815T2 (xx)	2000-08-21	Anksiyete ve gerginlik tedavisinde 1-ar(alk) ilimidazolin-2-tek kullan�m�
DE69701381T2 (de)	2000-11-16	Peptid-aldehydderivate als antikoagulierende mittel
AU2002251873A1 (en)	2002-08-19	Methods and compositions for modulating gluconeogenesis using pgc-1
DE60203726D1 (de)	2005-05-19	Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
AR009282A1 (es)	2000-04-12	Inhibidores moleculares de adhesion celular mediados por integrina beta2
EP0928792A3 (en)	2001-06-27	Bicyclic(3.1.0)hexanes and related compounds